Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 1,282,078	$ 1,204,924
Marketable securities	1,086,595	640,460
Accounts receivable, net	1,310,821	1,292,445
Due from unconsolidated joint business, net	323,714	283,360
Inventory	865,738	804,022
Other current assets	750,039	447,462
Total current assets	5,618,985	4,672,673
Marketable securities	2,101,796	1,470,652
Property, plant and equipment, net	1,837,670	1,765,683
Intangible assets, net	4,294,791	4,028,507
Goodwill	2,154,341	1,760,249
Investments and other assets	751,588	618,795
Total assets	16,759,171	14,316,559
Current liabilities:
Current portion of notes payable	3,262	3,136
Taxes payable	457,769	168,058
Accounts payable	282,702	229,178
Accrued expenses and other	1,812,099	1,819,334
Total current liabilities	2,555,832	2,219,706
Notes payable	576,207	582,061
Long-term deferred tax liability	138,403	50,656
Other long-term liabilities	915,731	650,096
Total liabilities	$ 4,186,173	$ 3,502,519
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	$ 0	$ 0
Common stock, par value $0.0005 per share	129	129
Additional paid-in capital	4,251,443	4,196,156
Accumulated other comprehensive loss	(101,025)	(59,488)
Retained earnings	11,033,736	9,283,919
Treasury stock, at cost	(2,611,706)	(2,611,706)
Total Biogen Inc. shareholders’ equity	12,572,577	10,809,010
Noncontrolling interests	421	5,030
Total equity	12,572,998	10,814,040
Total liabilities and equity	$ 16,759,171	$ 14,316,559